欧洲女性青少年和年轻成人（AYAs）乳腺癌的预后：EUROCARE-6回顾性队列结果

IF 7.9 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Pub Date : 2025-05-02 DOI:10.1016/j.breast.2025.104472

Alice Bernasconi , Angela Toss , Emma Zattarin , Seyed Mohsen Mousavi , Marcel Blum , Claudia E. Kuehni , Alexander Katalinic , Jan Trallero , Elisabetta Rapiti , Luigino Dal Maso , Laura Botta , Silvia Rossi , Fedro Peccatori , Annalisa Trama , the EUROCARE-6 Working Group

{"title":"欧洲女性青少年和年轻成人（AYAs）乳腺癌的预后：EUROCARE-6回顾性队列结果","authors":"Alice Bernasconi , Angela Toss , Emma Zattarin , Seyed Mohsen Mousavi , Marcel Blum , Claudia E. Kuehni , Alexander Katalinic , Jan Trallero , Elisabetta Rapiti , Luigino Dal Maso , Laura Botta , Silvia Rossi , Fedro Peccatori , Annalisa Trama , the EUROCARE-6 Working Group","doi":"10.1016/j.breast.2025.104472","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC) is the most common malignancy in AYA (15–39 years) females and is more aggressive than in adult women (40–69 years). However, an updated overview on BC in AYAs and how it differs from BC in adult women is lacking.</div></div><div><h3>Methods</h3><div>We used data from the EUROCARE-6 study to calculate incidence rates (IRs) of BC in AYA and adult women over the period 2001–2013 in Europe. We estimated 5-year and 10-year relative survival (RS) using period analysis. Stage at diagnosis distribution and conditional RS (CS) were used to investigate survival differences. We also reported cumulative incidence of multiple primary neoplasms (MPNs) in AYAs.</div></div><div><h3>Results</h3><div>The IR of BC in Europe was ∼18 per 100,000 in AYA females and more than ten-fold higher in adult women. Most BC cases were diagnosed at Stages I-II (74 % in AYAs vs 77 % in adults). Overall, AYAs had lower 5-year RS than adult women (85.0 % vs 89.5 %, respectively); the survival gap slightly decreased in CS. AYAs had worse survival than adult women for early stage and Stage III but better RS for Stage IV (5-year RS 31.5 % vs. 26.3 %). Cumulative incidence of all MPNs in AYAs was ∼6 % at 14 years from BC diagnosis.</div></div><div><h3>Conclusions</h3><div>Our findings support the more aggressive behavior of BC in AYAs. The high proportion of early stage at diagnosis is reassuring considering that organized BC screening is not available for AYAs in Europe. Conversely, the incidence of MPNs in AYAs is relevant and might deserve a revision of follow-up strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104472"},"PeriodicalIF":7.9000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognosis of Breast Cancer in European female adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results\",\"authors\":\"Alice Bernasconi , Angela Toss , Emma Zattarin , Seyed Mohsen Mousavi , Marcel Blum , Claudia E. Kuehni , Alexander Katalinic , Jan Trallero , Elisabetta Rapiti , Luigino Dal Maso , Laura Botta , Silvia Rossi , Fedro Peccatori , Annalisa Trama , the EUROCARE-6 Working Group\",\"doi\":\"10.1016/j.breast.2025.104472\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Breast cancer (BC) is the most common malignancy in AYA (15–39 years) females and is more aggressive than in adult women (40–69 years). However, an updated overview on BC in AYAs and how it differs from BC in adult women is lacking.</div></div><div><h3>Methods</h3><div>We used data from the EUROCARE-6 study to calculate incidence rates (IRs) of BC in AYA and adult women over the period 2001–2013 in Europe. We estimated 5-year and 10-year relative survival (RS) using period analysis. Stage at diagnosis distribution and conditional RS (CS) were used to investigate survival differences. We also reported cumulative incidence of multiple primary neoplasms (MPNs) in AYAs.</div></div><div><h3>Results</h3><div>The IR of BC in Europe was ∼18 per 100,000 in AYA females and more than ten-fold higher in adult women. Most BC cases were diagnosed at Stages I-II (74 % in AYAs vs 77 % in adults). Overall, AYAs had lower 5-year RS than adult women (85.0 % vs 89.5 %, respectively); the survival gap slightly decreased in CS. AYAs had worse survival than adult women for early stage and Stage III but better RS for Stage IV (5-year RS 31.5 % vs. 26.3 %). Cumulative incidence of all MPNs in AYAs was ∼6 % at 14 years from BC diagnosis.</div></div><div><h3>Conclusions</h3><div>Our findings support the more aggressive behavior of BC in AYAs. The high proportion of early stage at diagnosis is reassuring considering that organized BC screening is not available for AYAs in Europe. Conversely, the incidence of MPNs in AYAs is relevant and might deserve a revision of follow-up strategies.</div></div>\",\"PeriodicalId\":9093,\"journal\":{\"name\":\"Breast\",\"volume\":\"82 \",\"pages\":\"Article 104472\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2025-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0960977625004898\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977625004898","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

乳腺癌（BC）是AYA（15-39岁）女性中最常见的恶性肿瘤，比成年女性（40-69岁）更具侵袭性。然而，关于aya患者的BC以及其与成年女性的BC有何不同的最新综述是缺乏的。方法：我们使用EUROCARE-6研究的数据来计算2001-2013年欧洲AYA和成年女性BC的发病率（IRs）。我们使用周期分析估计5年和10年的相对生存（RS）。采用分期诊断分布和条件RS （CS）来研究生存差异。我们还报道了AYAs中多发性原发肿瘤（mpn）的累积发病率。结果在欧洲，AYA女性中BC的IR为每10万人中18人，成年女性的IR高出10倍以上。大多数BC病例在I-II期被诊断出来（青少年为74%，成人为77%）。总体而言，AYAs的5年生存率低于成年女性（分别为85.0%和89.5%）；CS组生存间隙略有减小。在早期和III期，aya患者的生存率低于成年女性，但IV期的RS较好（5年RS为31.5%比26.3%）。在BC诊断后14年，AYAs中所有mpn的累积发病率约为6%。结论研究结果支持BC在AYAs中具有更强的侵袭性行为。考虑到有组织的BC筛查在欧洲无法用于AYAs，早期诊断的高比例令人放心。相反，在AYAs中mpn的发生率是相关的，可能值得修订后续策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prognosis of Breast Cancer in European female adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results

Background

Breast cancer (BC) is the most common malignancy in AYA (15–39 years) females and is more aggressive than in adult women (40–69 years). However, an updated overview on BC in AYAs and how it differs from BC in adult women is lacking.

Methods

We used data from the EUROCARE-6 study to calculate incidence rates (IRs) of BC in AYA and adult women over the period 2001–2013 in Europe. We estimated 5-year and 10-year relative survival (RS) using period analysis. Stage at diagnosis distribution and conditional RS (CS) were used to investigate survival differences. We also reported cumulative incidence of multiple primary neoplasms (MPNs) in AYAs.

Results

The IR of BC in Europe was ∼18 per 100,000 in AYA females and more than ten-fold higher in adult women. Most BC cases were diagnosed at Stages I-II (74 % in AYAs vs 77 % in adults). Overall, AYAs had lower 5-year RS than adult women (85.0 % vs 89.5 %, respectively); the survival gap slightly decreased in CS. AYAs had worse survival than adult women for early stage and Stage III but better RS for Stage IV (5-year RS 31.5 % vs. 26.3 %). Cumulative incidence of all MPNs in AYAs was ∼6 % at 14 years from BC diagnosis.

Conclusions

Our findings support the more aggressive behavior of BC in AYAs. The high proportion of early stage at diagnosis is reassuring considering that organized BC screening is not available for AYAs in Europe. Conversely, the incidence of MPNs in AYAs is relevant and might deserve a revision of follow-up strategies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast 医学-妇产科学

CiteScore

8.70

自引率

2.60%

发文量

165

审稿时长

59 days

期刊介绍： The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.